Published in Breast J on December 11, 2007
Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet (2008) 1.82
Hereditary diffuse gastric cancer: prophylactic surgical oncology implications. Surg Clin North Am (2008) 1.00
Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer. Hugo J (2010) 0.98
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert Rev Mol Diagn (2012) 0.97
Identification of Novel Susceptibility Genes for Breast Cancer - Genome-Wide Association Studies or Evaluation of Candidate Genes? Breast Care (Basel) (2009) 0.96
OVARIAN CANCER SUICIDE GENE THERAPY WITH GENETICALLY ENGINEERED, TRANSGENICALLY EXPRESSED, INTRACELLULAR scFv ANTIBODIES AGAINST ANTI-OXIDATIVE ENZYMES. Proc S Dak Acad Sci (2008) 0.80
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Colorectal cancer. Lancet (2010) 8.36
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med (2006) 5.70
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2004) 3.86
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2008) 3.76
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol (2005) 3.44
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol (2014) 3.07
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer (2008) 2.95
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst (2008) 2.78
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ (2014) 2.60
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res (2004) 2.51
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis (2002) 2.41
Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer (2004) 2.32
Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev (2006) 2.04
Familial myeloma. N Engl J Med (2008) 1.96
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Comparison of extended colectomy and limited resection in patients with Lynch syndrome. Dis Colon Rectum (2010) 1.88
Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. Fam Cancer (2007) 1.82
Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet (2003) 1.80
Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res (Phila) (2010) 1.80
Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol (2006) 1.79
Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.78
Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways. J Infect Dis (2002) 1.77
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut (2007) 1.68
Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo. J Cell Biol (2004) 1.63
Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril (2013) 1.62
Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol (2009) 1.61
Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet (2006) 1.59
The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer (2005) 1.57
Familial sarcoma: challenging pedigrees. Cancer (2003) 1.54
What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. Ann Intern Med (2012) 1.54
Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. J Clin Oncol (2003) 1.53
Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol (2013) 1.52
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol (2005) 1.50
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer (2005) 1.48
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Breast J (2009) 1.48
Genital human papillomavirus testing by in situ hybridization in liquid atypical cytologic materials and follow-up biopsies. Acta Cytol (2005) 1.48
Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer (2006) 1.47
Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer (2008) 1.45
ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res (2008) 1.43
Whole genome expression profiling reveals a significant role for immune function in human abdominal aortic aneurysms. BMC Genomics (2007) 1.39
Hereditary nonpolyposis colorectal carcinoma (HNPCC) and HNPCC-like families: Problems in diagnosis, surveillance, and management. Cancer (2004) 1.39
MGUS, multiple myeloma, and paratarg-7. Lancet Oncol (2009) 1.39
Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res Treat (2010) 1.38
Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer (2003) 1.38
Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer. Breast Cancer Res Treat (2015) 1.37
Review of juxtaglomerular cell tumor with focus on pathobiological aspect. Diagn Pathol (2011) 1.36
Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases. Virchows Arch (2010) 1.32
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer (2008) 1.28
A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev (2005) 1.27
The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol (2005) 1.27
A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. JAMA (2004) 1.26
Who should be sent for genetic testing in hereditary colorectal cancer syndromes? J Clin Oncol (2007) 1.26
Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer (2004) 1.25
Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families. Cancer Genet Cytogenet (2006) 1.25
Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J Biol Chem (2002) 1.24
Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A (2002) 1.23
Molecular screening for the Lynch syndrome--better than family history? N Engl J Med (2005) 1.22
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. J Natl Cancer Inst (2010) 1.21
Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control (2005) 1.20
Intraosseous lipoma. A clinical, radiologic, and pathologic study of 5 cases. Ann Diagn Pathol (2007) 1.19
Regional expression of HOXA4 along the aorta and its potential role in human abdominal aortic aneurysms. BMC Physiol (2011) 1.19
MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res (2004) 1.18
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.17
TGFBR1*6A may contribute to hereditary colorectal cancer. J Clin Oncol (2005) 1.16
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat (2013) 1.16
Infarcted fibroadenoma of the breast: report of two new cases with review of the literature. Diagn Pathol (2013) 1.15
Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol (2011) 1.14
The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol (2006) 1.14
Pancreatic cancer and the FAMMM syndrome. Fam Cancer (2007) 1.13
Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients. Clin Dev Immunol (2010) 1.12
let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor α signaling in breast cancer. Mol Med (2011) 1.11
Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. PLoS One (2013) 1.10
Tobacco use and increased colorectal cancer risk in patients with hereditary nonpolyposis colorectal cancer (Lynch syndrome). Arch Intern Med (2004) 1.10
Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2012) 1.10
BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet (2005) 1.09
Suspected HNPCC and Amsterdam criteria II: evaluation of mutation detection rate, an international collaborative study. Int J Colorectal Dis (2002) 1.09
IkappaB kinase is a critical regulator of chemokine expression and lung inflammation in respiratory syncytial virus infection. J Virol (2004) 1.09